Zymeworks Revenue and Competitors
Estimated Revenue & Valuation
- Zymeworks's estimated annual revenue is currently $22.5M per year.
- Zymeworks received $110.6M in venture funding in June 2018.
- Zymeworks's estimated revenue per employee is $85,840
- Zymeworks's total funding is $845.8M.
- Zymeworks's current valuation is $696.9M. (January 2022)
Employee Data
- Zymeworks has 262 Employees.
- Zymeworks grew their employee count by 0% last year.
Zymeworks's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Research | Reveal Email/Phone |
2 | VP Human Resources and DEI | Reveal Email/Phone |
3 | SVP, Corporate Secretary and General Counsel | Reveal Email/Phone |
4 | vp TECHNOLOGY | Reveal Email/Phone |
5 | Associate Director, Legal | Reveal Email/Phone |
6 | Chief People Officer | Reveal Email/Phone |
7 | Director Quality Assurance | Reveal Email/Phone |
8 | Executive Director, FP&A and Corporate Finance | Reveal Email/Phone |
9 | Director Preclinical Research | Reveal Email/Phone |
10 | Senior Director, Medical Writing | Reveal Email/Phone |
Zymeworks Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.5M | 132 | 8% | $1.4B | N/A |
What Is Zymeworks?
Zymeworks Inc. (NYSE/TSX: ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC) and is expected to be the subject of an Investigational New Drug (IND) filing in 2018. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, and Janssen.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$845.8M
Total Funding
262
Number of Employees
$22.5M
Revenue (est)
0%
Employee Growth %
$696.9M
Valuation
N/A
Accelerator
Zymeworks News
Zymeworks is developing bispecific antibodies that recognize two different molecular targets simultaneously, as well as other types of...
By Anirban Sen. (Reuters) -Investment firm All Blue Capital has approached Zymeworks Inc, a developer of antibody therapies for cancer,...
Vancouver, Canada-based Zymeworks develops antibody treatments for different types of cancer and is currently working on clinical trials for a...
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) • HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tislelizumab, versus standard of care • Phase 2 data demon ...
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers Vancouver, British Columbia (October 26, 2021) - Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothera ...
Other Companies in Vancouver
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $77.8M | 262 | 4% | N/A |
#2 | $73.2M | 262 | -7% | N/A |
#3 | $1.2M | 264 | 55% | $171M |
#4 | $78.7M | 265 | -9% | N/A |
#5 | $43.7M | 265 | 4% | N/A |
Zymeworks Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-06-12 | $110.6M | Undisclosed | Citigroup Global Markets Canada Inc | Article |